<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764735</url>
  </required_header>
  <id_info>
    <org_study_id>18-110-0004</org_study_id>
    <nct_id>NCT03764735</nct_id>
  </id_info>
  <brief_title>Study of SkQ1 as Treatment for Dry-eye Syndrome</brief_title>
  <acronym>VISTA-1</acronym>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitotech, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitotech, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and
      effective compared to placebo for the treatment of the signs and symptoms of dry eye
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over
      the course of approximately 9 weeks. Qualified subjects are randomized 1:1:1 to receive
      either High Dose SkQ1 ophthalmic solution, Low Dose SkQ1 ophthalmic solution, or Placebo
      (vehicle of SkQ1 ophthalmic solution).

      The Primary Endpoints are:

      Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;

      Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Actual">February 9, 2019</completion_date>
  <primary_completion_date type="Actual">February 9, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-group study of two strengths of ophthalmic solution versus placebo solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Corneal Staining change from baseline</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of Corneal Fluorescein Staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grittiness change from baseline</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of patient-reported grittiness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal and conjunctival staining</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Corneal and conjunctival fluorescein staining on a 0-4 point scale in all regions through Day 57 and following exposure to a controlled adverse environment (CAEÂ®) on Day 57 only. Regions: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum and total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lissamine green staining</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Lissamine green staining in all regions Scale; regions: central, superior, inferior, temporal, nasal, corneal sum, and total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's Test</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Unanesthetized Schirmer's Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Discomfort and 4-symptom Questionaire</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Discomfort &amp; 4-Symptom Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSDI</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Surface Disease Index (OSDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Discomfort</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Ocular Discomfort Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Diary</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Subject Symptom Daily Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Breakup Time</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Tear Film Breakup Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Conjunctival Redness Scale Conjunctival Redness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Margin Redness</measure>
    <time_frame>Through Day 57</time_frame>
    <description>Lid Margin Redness Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>SkQ1 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SkQ1 (Vehicle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose - SkQ1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose - SkQ1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose - SkQ1</intervention_name>
    <description>SkQ1 Low dose ophthalmic solution</description>
    <arm_group_label>Low Dose - SkQ1</arm_group_label>
    <other_name>Vizomitin(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose - SkQ1</intervention_name>
    <description>SkQ1 High Dose ophthalmic solution</description>
    <arm_group_label>High Dose - SkQ1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SkQ1 (Vehicle)</intervention_name>
    <description>Vehicle for SkQ1 ophthalmic solution</description>
    <arm_group_label>SkQ1 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye;

          -  Have a history of use of eye drops for dry eye symptoms ;

          -  Ocular Discomfort;

          -  Schirmer's Test score;

          -  Have corneal fluorescein staining ;

          -  Have lissamine green conjunctival Staining ;

          -  Have a conjunctival redness;

        Exclusion Criteria:

          -  Have participated in the previous SkQ1 ophthalmic solution Phase 2 treatment study;

          -  Have any clinically significant slit lamp findings at Visit 1;

          -  Be diagnosed with an ongoing ocular infection or active ocular inflammation at Visit
             1;

          -  Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned
             over the study period;

          -  Have an uncontrolled systemic disease;

          -  Be a woman who is pregnant, nursing or planning a pregnancy;

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control;

          -  Have a known allergy and/or sensitivity to the study drug or its components ;

          -  Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study;

          -  Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days of Visit 1;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence T Friedhoff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mitotech, SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea &amp; Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Insititute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Eye Clinic</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>SkQ1</keyword>
  <keyword>KCS</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

